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Targeting androgen receptor (AR) has been shown to be promising in treating
glioblastoma (GBM) in cell culture and flank implant models but the mechanisms remain
unclear. AR antagonists including enzalutamide are available for treating prostate cancer
patients in clinic and can pass the blood–brain barrier, thus are potentially good
candidates for GBM treatment but have not been tested in GBM orthotopically. Our
current studies confirmed that in patients, a majority of GBM tumors overexpress AR in
both genders. Enzalutamide inhibited the proliferation of GBM cells both in vitro and in
vivo. Although confocal microscopy demonstrated that AR is expressed but not
specifically in glioma cancer stem cells (CSCs) (CD133+), enzalutamide treatment
significantly decreased CSC population in cultured monolayer cells and spheroids,
suppressed tumor sphere-forming capacity of GBM cells, and downregulated CSC
gene expression at mRNA and protein levels in a dose- and time-dependent manner.
We have, for the first time, demonstrated that enzalutamide treatment decreased the
density of CSCs in vivo and improved survival in an orthotopic GBM mouse model. We
conclude that AR antagonists potently target glioma CSCs in addition to suppressing the
overall proliferation of GBM cells as a mechanism supporting their repurposing for clinical
applications treating GBM.
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INTRODUCTION
Glioblastoma (GBM) is the most common type of malignant
central nervous system tumor in adult patients in the US
accounting for about 50% of them (1). Standard treatment for
GBM includes maximal safe resection of the tumor, followed by
concurrent chemoradiation and adjuvant chemotherapy. Some
of the recent promising studies focused on identification of
aberrant genetic and signaling pathways to develop small
molecules for targeted therapies, characterization of
glioblastoma cancer stem cells, modulation of tumor
immunological responses and understanding of the rare long-
term survivors (2–9). However, even with the extensive efforts of
research, current standard care using temozolomide
concurrently with brain radiation therapy (RT) after maximal
safe surgery only achieves a median survival of fourteen months
in the overall patient population, or 22 months in the best
prognostic group of patients carrying a hypermethylated
MGMT promotor (10, 11). With this universally fatal disease
due to its resistance to the standard treatment of RT and
chemotherapy, any research advances even small may have a
significant impact on survival and provide hope to the thousands
of patients who are diagnosed annually with this cancer.
With extensive research conducted to comprehend the
molecular regulation of GBM for potential clinical applications,
our present knowledge about the tumorigenesis of GBM remains
limited. Interestingly, the incidence rate of GBM is significantly
higher in adult men than in women as reviewed by Kabat et al.
(12). Overall the incidence rate of all glioma in adulthood is also
50% greater in men than in women (13, 14). The exact
mechanism underlying this pronounced epidemiology is
unclear. Using New York State tumor registry data for the
period from 1976 to 1995, McKinley et al. calculated crude,
and age- and sex-specific incidence rates for three types of
gliomas: glioblastoma, astrocytoma not otherwise specified, and
anaplastic astrocytoma (15). Results showed that, overall, males
were 1.5 to 2.0 times more likely to develop GBM compared with
females even with age justification. In addition, experimental
studies indicate that glioblastomas transplanted into animals
grow at a slower rate in females compared with males (16).
The oncogenic potential of sexual hormones and androgen/
androgen receptors cannot be ruled out in the carcinogenesis
of GBM. Indeed, steroid hormone receptors including androgen
receptor (AR) are members of a superfamily of ligand-activated
transcription factors that are potentially oncogenic in gliomas as
has been proposed by other researchers (17, 18) and has been
confirmed in prostate cancer (19).
In contrast to estrogen receptors (ERs) and progesterone
receptors (PRs) whose expressions in human and animal
glioma and glioblastoma cell lines are varied and inconsistent
(20–26), androgen receptors were consistently detected in a high
proportion of gliomas. For example, Caroll et al. investigated the
expression of the androgen, estrogen, glucocorticoid, and
progesterone receptor messenger ribonucleic acid (mRNA) and
protein in a number of astrocytic neoplasms of various
histological grades (17). Androgen mRNA was detected in all
astrocytic neoplasms examined, regardless of histological subtype.
Estrogen receptor mRNA was undetectable in all astrocytic
tumors examined in that study. Chung et al. detected AR
expression immunohistochemically in 40% of GBMs (grade IV
gliomas) and 75% of anaplastic astrocytomas (grade III gliomas)
(27). Interestingly, AR expression was also present in 39% of the
female glioma samples, similar to the detectable ratio in male
(47%). A more recent study from Yu et al. confirmed significantly
upregulated AR expression in the GBM tissue as compared to
normal peripheral brain tissue in patients by Western blotting
assays. Furthermore, AR expression was detected in all eight
human GBM cell lines used in this study (28).
AR mediates androgen effects via hormone-receptor binding
in normal tissues in both male and female although androgen-
independent AR activation is a common finding in castration-
resistant prostate cancers. Androgens derive predominantly
from the testis but also to a lesser extent from the adrenal
glands. Testicular testosterone and adrenal (source for females)
dehydroepiandrosterone (DHEA) or androstenedione can be
converted into bioactive 5a-dihydrotestosterone (DHT) by the
enzymes 5 alpha-reductase, which binds to the AR and induces
its conformational change. This leads to the dissociation of
chaperone and heat shock proteins and the subsequent
interaction between AR and co-regulatory molecules and
importin a, which facilitates nuclear translocation of AR–
ligand complexes. In the nucleus, the AR undergoes
phosphorylation and dimerization, which permits chromatin
binding to androgen-responsive elements (ARE) within
androgen-regulated target genes (29).
To our knowledge, despite these preliminary expression
pattern studies of AR in GBM and its known functions/
signaling in prostate cancer, there has been no reported studies
in confirming the therapeutic role of targeting AR in GBM in
brain although a previous study from Zalcman et al. and a very
recent report from Werner et al. showed promising results in
flank implant models (30, 31). Therefore, we used a syngeneic
orthotopic mouse model to test the hypothesis that AR
suppression using the AR antagonist, enzalutamide, is effective
to suppress tumor growth in the brain. We also studied the
expression pattern of AR in GBM tumor specimens from
patients treated at our medical center. Simultaneous
experiments were conducted in the laboratory on the
mechanism of AR inhibition in GBM cell lines in which AR
expression status was correlated to the effects of AR inhibition on
anchorage-dependent cell growth, tumor sphere formation, as
well as cancer stem cell survival/marker gene expression.
MATERIALS AND METHODS
Cell Culture
U138MG (TP53 mutant and PTEN mutant), U87MG (TP53
widetype and PTEN mutant) and Ln229 (TP53 mutant and
PTEN widetype) cells were purchased from American Type
Culture Collection (ATCC) (Manassas, VA, USA). MGPP-3
(PDGF+, P53−/−, PTEN−/−) which is a murine GBM cell line
was kindly provided by Dr. Peter Canoll (Columbia University,
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New York, NY, U.S.) (32, 33). This cell line was generated from
primary cultures from a mouse GBM tumor model induced by
injection of VSVG-pseudotyped PDGF-IRES-Cre (PIC)
retrovirus, which expresses PDGF and Cre in one transcript,
into rostral subcortical white matter (WM) of transgenic mice
that carry floxed Pten and p53 (Ptenf/f; p53f/f), and stop-floxed
luciferase reporter. The human GBM cells were cultured in
DMEM (Thermo Fisher Scientific, Inc., Waltham, MA, USA)
or EMEM (ATCC, Manassas, VA, USA) per provider’s
recommendation supplemented with 10% fetal bovine serum
(FBS) (Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100
U/ml penicillin and 100 mg/ml streptomycin in a humidified
incubator with 5% CO2 at 37°C. Murine GBM cells were cultured
with previously published protocol (32, 33).
Cell Proliferation Assay
Cell titer blue assays were performed with cells cultured in 96-
well plates treated with different concentrations of AR
antagonists (enzalutamide and bicalutamide (Selleckchem,
Munich, Germany) for 48 h before changing to fresh media
and continuing culture overnight. 20 µl cell titer blue reagents
(Promega, Madison, WI, USA) were added to each well
containing 100 µl medium. After incubation at 37°C for 2 h,
the fluorescence was read at 560/590 nm using SpectraMax
(Molecular Devices, San Jose, CA, USA). IC50s of AR
antagonists on GBM cell lines were calculated using the
GraphPad software (Version 8.3.1, San Diego, CA, USA).
Confocal Immunofluorescence
Microscopsy
U87MG, U138MG, and MGPP3 GBM cell lines were treated
with DMSO (control), 20 µM, or 40 µM enzalutamide for 48 h.
Cells were fixed with 4% paraformaldehyde for 10 min at room
temperature, permeabilized with 0.5% Triton X-100 for 10 min
and then washed in PBST three times. Cells were blocked with
1% BSA for 30 min and then incubated with the primary
antibodies for 1 h at room temperature. The primary
antibodies include anti-c-Myc (1:100) (Abcam, Cambridge,
MA, USA) and AR antibody (441) (1:50) (Santa Cruz
Biotechnology, Inc., Dallas, TX, USA). After incubating with
primary antibodies, cells were washed with PBST three times,
5 min each and then incubated with secondary antibody
conjugated with Alexa Fluor 488 or Alexa Fluor 647 (Abcam,
Cambridge, MA, USA) for 1 h at room temperature. Cell nuclei
were stained with DAPI mounting medium (Thermo Fisher
Scientific Inc., Waltham, MA, USA) before captured with the
LSM800 confocal microscope (ZEISS, Germany). Similar
procedures were performed for FFPE mouse brain tumor
specimens for confocal microscopy with the following primary
antibodies used: anti-AR antibody (ab3510) (Abcam,
Cambridge, MA, USA), anti-Nanog (PA5-85110) (Thermo
Fisher Scientific Inc., Waltham, MA, USA), and anti-CD133
antibody (ab19898) (Abcam, Cambridge, MA, USA). The
weighted colocalization was analyzed for 4 different areas of
the confocal images using ZEN colocalization software
(ZEISS, Germany).
Tumor Spheroid Formation and Treatment
U87MG and MGPP3 cells were cultured in media with 0.5% FBS
in 96-well plates (ultra-low attachment) (Corning, Inc., Corning,
NY, USA) at a density of 10,000/well and maintained at 37°C
under 5% CO2 in a humidified incubator. After tumor spheroids
were formed, DMSO (control), enzalutamide, or bicalutamide at
specified concentrations were added into culture media. The
diameters of the spheroids were monitored every day for an
additional 3–4 days under a microscope and growth curves of the
spheroids were plotted and compared between groups.
Flow Cytometry on Cancer Stem Cells in
Tumor Spheroids/Cell Culture
The subpopulation of cancer stem cells in GBM tumor spheroids
or cultured adherently were sorted and evaluated with and
without enzalutamide treatment, respectively, with an anti-
CD133 CSC surface antibody (Miltenyi Biotec, Germany).
After treating the tumor spheroids for 4 days with 120 µM
enzalutamide or 180 µM bicalutamide, the tumor spheroids were
harvested, gently dissociated to single cell suspensions using
ACCUTASE™ (STEMCELL Technologies Inc., Canada). First
a total of 106 cells were stained with Live/Dead fixable dead cell
staining dyes and then incubated with APC-conjugated anti-
CD133 antibody (Miltenyi Biotec, Germany). After 30 min of
incubation with CD133 antibody at 4°C, cells were washed with
phosphate-buffered saline (PBS) at 300×g for 10 min. Samples
were sorted using a FACS LSRII G Flow Cytometer and
percentages of CSC subpopulation were analyzed by FACSDiva
software (Beckon-Dickinson, Franklin Lakes, NJ, USA).
Limiting Dilution Assays In Vitro and
In Vivo on Stem Cell Content
To determine the content of CSCs or stem-like cells in the
cultured GBM cell lines with or without enzalutamide
treatment, U87MG or MGPP3 cells were treated with DMSO
(control) and enzalutamide for 2 days in adherent cultures before
being trypsinized and dissociated into suspended single cells. A
series of numbers of suspended single cells were seeded in ultra-
low attachment 96-well plates (Corning, Inc., Corning, NY,
USA) at 1, 10, 25, 50 and 100 cells/well and cultured in media
with 0.5% FBS for 14 days with an intermittent assessment to
confirm the formation of tumor spheroids. After 14 days, the
numbers of wells that have at least one sphere were counted
manually under a microscope.
To further confirm the change of CSCs with or without
enzalutamide treatment, orthotopic LDA in vivo experiment
was performed. MGPP3 cells were treated with DMSO
(control) or enzalutamide for 3 days before dissociating into
single cells. 103 and 104 cells with or without enzalutamide
treatment were inoculated into six mice brain for each group.
The growth of tumor was monitored using PerkinElmer In vivo
Imaging System (IVIS) every week.
The frequency of CSCs or stem-like cells was calculated using
an Extreme Limiting Dilution Algorithm (ELDA software;http://
bioinf.wehi.edu.au/software/elda/).
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Western Blotting
After treating U87MG spheroids with 120 µM enzalutamide for 1
day or 3 days, the cell pellets were homogenized with RIPA Lysis
and Extraction Buffer (Thermo Fisher Scientific Inc., Waltham,
MA, USA) with a mixture of protease inhibitors (Thermo Fisher
Scientific Inc.). The protein concentrations were determined using
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific
Inc.) . Cel l lysates containing 100 µg protein were
electrophorized on 4–20% Tris-Glycine SDS-PAGE gel (Thermo
Fisher Scientific Inc.). The primary antibodies used in this
experiment include polyclonal antibody Nanog (PA5-85110,
1:1,000) (Thermo Fisher Scientific Inc.), monoclonal anti-Oct4
antibody (ab181557, 1:500) (Abcam, Cambridge, MA, USA),
polyclonal anti-AR antibody (ab3510, 1:500) (Abcam,
Cambridge, MA, USA), monoclonal anti-c-Myc (ab32072,
1:1,000) (Abcam, Cambridge, MA, USA), monoclonal ani-
CDC25A (DCS-120) (MA5-13794, 1:1,000) (Thermo Fisher
Scientific Inc.), polyclonal anti-GADD45A (ab180768, 1:1,000)
(Abcam, Cambridge, MA, USA), polyclonal anti-FOXO3a
(ab70315, 1:1,000) (Abcam, Cambridge, MA, USA), polyclonal
anti-GATA4 (PA1-102, 1:1,000) and monoclonal anti-b-actin
(AC-74, 1:3,000) (MilliporeSigma, Burlington, MA, USA). All
these antibodies have cross-reactivity against both human and
murine antigens. After incubating the blots with the primary
antibody overnight at 4°C, the blots were washed three times for
5 min with TBST and then incubated with the IRDye 800CW
Goat Anti-Rabbit LgG (H+L) or IRDye 800CWGoat Anti-Mouse
LgG (H+L) secondary antibodies (Li-Cor Biotechnology, Lincoln,
NE, USA) for 1 hour at room temperature. The blots were
scanned with densitometry performed using Odyssey XL imager
and provided software (Li-Cor Biotechnology, Lincoln, NE, USA)
CSC Marker Gene Expression Analysis
With TCGA Database
Spearman’s rank correlation coefficients of mRNA expression
levels between AR and various CSC marker genes were calculated
based on RNA-seq results of GBM patients from TCGA database.
RNA-seq and Quantitative Real-Time PCR
U87MG cells were treated with 80 µM enzalutamide for 4, 24,
and 48 h before the total RNA was isolated using RNeasy Plus
Mini Kit (Qiagen, Netherlands). The RNA-seq was performed by
next-generation sequencing (NGS) using NextSeq550 (Illumina,
San Diego, CA, USA). For data analyses, each RNA-seq read was
trimmed using Trimmomatic (34) to make sure the average
quality score is larger than 30 and the minimum length being 30
bp or longer. Reads were mapped to the human genome (NCBI
build 37) using Tophat v2.1.1 (35), which together accurately
aligned an average of 90% of paired-end reads. Numbers of reads
in genes were counted by the software tool of HTSeq-count (36)
using corresponding human gene annotations and the “union”
resolution mode was used. Differential expressions were
computed for whole gene regions by summing reads for each
region. For pair-wise differential expression comparisons, DESeq
(v.1.36.0) (37) was used to analyze the numbers of reads aligned
to genes and to identify differentially expressed genes. A
threshold value for fold-change of differential expression was
set at log2 (fold-change) >1 (two-fold actual value) and adjusted
P-values <0.05 for rejecting the null hypothesis.
Quantitative real time PCR (qPCR) was performed using
Taqman probes from Applied Biosystems (Thermo Fisher
Scientific Inc.) on the reversely transcribed cDNAs from the
same RNA samples used in RNA-seq to confirm the changes of
the genes with or without enzalutamide treatment. Fold changes
of the gene expression levels were calculated by the delta Ct
method relative to the control samples. The beta-actin was used
as internal control for normalization.













Syngeneic Orthotopic GBM Mouse Model
5 × 104 MGPP3 murine glioblastoma cells were stereotactically
implanted into the right brain hemisphere of 16 to 17 week-old
male mice weighing 20 to 30 g. The growth of the tumor was
monitored using PerkinElmer In vivo Imaging System (IVIS)
each week. Mice were imaged 10 min after intraperitoneal
injection of luciferin (Biosynth International, Inc., Itasca, IL,
USA) at 150 mg/kg. The mice were regrouped into vehicle
(negative control) (10% DMSO, 30% PEG400, 60% corn oil) or
enzalutamide treatment groups with equivalent mean values of
bioluminescence signals between groups at week 5 after the
implantation. Enzalutamide (20 mg/kg, dissolved in the vehicle
solution, 100 µl/injection) or vehicle only (100 µl/injection) were
injected intraperitoneally (IP) into the mice three times per week
per previously published protocols (38). The treatment was
continually given to the mice until week 15 after the
implantation (week 10 after starting drug treatment) or death.
The mice presented with signs of near death such as seizures
were euthanized with neck dislocation. After death was
confirmed, mice were perfused with 10% formalin in PBS and
brain tissues were dissected for immunohistochemistry (IHC)
studies. All studies were carried out in compliance with the local
ethical guidelines for animal experiments. The protocol was
approved by the Institutional Animal Care and Use Committee
(IACUC) of University of Nebraska Medical Center (protocol #:
16-134-01). All the mice with tumor received palliative care for
pain control after surgery, during the follow-up and prior to
euthanization per institutional guidelines.
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Immunohistochemistry
Serial unstained slides were cut from the formalin-fixed paraffin-
embedded (FFPE) tissue blocks of GBM specimens from deceased,
normal brain autopsy tissue from patients who died of non-
neurological disease, and temporal lobectomy surgical specimens
from patients with epilepsy with approved protocol from our
Institutional Review Board. IHC for AR (clone SP107 rabbit
monoclonal antibody, Cell Marque, Rocklin, CA, USA) was
performed using BenchMark Ultra IHC/ISH system (Roche, Basel,
Switzerland). Slides cut from the FFPE mouse brain GBM tissue
were incubated with anti-AR (ab3510), anti-CD133 (ab19898), anti-
Sox2 (ab97959) and anti-c-Myc (ab32072) individually or in
combination. All these antibodies were from Abcam, Cambridge,
MA, USA. After staining for the above markers with substrates
incubated and color developed, slides were scanned with Ventana
iScan HT slide scanner at 400× magnification and quantified using
Definiens Tissue Studio (Ventana, Munich, Germany).
Statistics
Experimental data for cell proliferation assays, tumor spheroid
sizes and IHC signals were calculated as Mean ± standard error
of the mean. Student t-test (two groups) or one-way ANOVA
(more than two groups) was performed using GraphPad
Software (Version 8.3.1, San Diego, CA, USA). Overall
survivals (OS) were compared between enzalutamide treatment
and vehicle only groups of mice with Kaplan–Meier analysis.
Results were considered statistically significant if p <0.05.
RESULTS
AR Is Commonly Overexpressed in GBM
Tumor Specimen From Patients
We performed immunohistochemistry (IHC) studies on tumor
specimens from GBM patients and demonstrated overexpression
of AR in tumor tissues when compared with control brain
specimens (brain tissue from patients without neurologic
disease/tumor or patients with temporal lobectomy for epilepsy
as shown in Figure 1). The majority of both male and female
GBMs were found to have high AR nuclear expression levels
in a significant percentage of cells in tumor (Figures 1F, L). We
observed the pattern of peri-arterially enriched AR expression
(Figure 1K). In normal brain tissue controls from autopsy, no
AR expression was detected (Figure 1Q). Similarly, lobectomy
tissue from epilepsy patients showed very low AR expression
detected in very few cells (Figure 1R). Forty-three out of 58 GBM
patients (74%) examined so far in our database display positive
AR expression in >10% tumor cell nuclei, with the other eleven
patients showing 1–10% positivity (93% with >1% positivity) and
only four patients’ tumor were found to be completely devoid of
AR staining. Ninety-seven percent male and 87.5% female
patients, respectively, were found to be positively stained for
AR in >1% of tumor cell nuclei (P = 0.33). Seventy-nine percent
male and 66.7% female patients showed positive AR staining
in >10% tumor cell nuclei (P = 0.30). Reviewing of the staining
pattern and positivity counting were performed independently
by two pathologists from our institute with a high level
of consistency.
AR Antagonists Inhibit the Proliferation of
GBM Cells In Vitro
We demonstrated that in commercially available GBM cell lines
including A172, Ln229, M059K, U87MG and U138MG, all are
AR-positive but with variable expression levels (Figure 1S). Our
results are consistent with the finding from Yu et al. who showed
all twelve GBM cell lines tested were expressing AR (28). AR
antagonists, enzalutamide or bicalutamide, inhibited the
proliferation of GBM cells and significantly reduced viability
after two days of treatment in a dose-dependent manner in all
human and murine GBM cell lines tested in vitro (Figure 2). The
GBM cells’ sensitivity to the drug was not found to be related to
the level of AR expression. Even though AR expression levels are
relatively low in some cell lines such as U87MG and Ln229, they
were still susceptible to AR antagonists with IC50s of
enzalutamide and bicalutamide being ~40 and 80–160 µM,
respectively, for all tested human GBM cell lines.
Enzalutamide Downregulates
c-Myc and AR Expression in a
Dose-Dependent Manner
c-Myc, an extensively studied oncogene, has an important role in
ensuring tumor development, promoting proliferation and
maintenance of cancer progenitor cells in human cancers (39–
41). c-Myc, along with other stem cell genes including SOX2,
BMI1 and OCT-4, is highly expressed in prostate cancer stem/
progenitor cells (42). We studied the relationship between c-Myc
expression and AR blockade in GBM cells. Human prostate cancer
cell line LnCap, an AR-positive cell line, was used as a positive
control for AR and c-Myc expression in GBM cells (Figure 3A).
Both AR and c-Myc expression levels in U87MG and MGPP3 cell
lines were downregulated after 20 µM enzalutamide treatment for
24 h, and both decreased further with higher concentration of
enzalutamide (40 µM) (Figures 3B, D). The downstream genes of
c-Myc such as FOXO3a and CDC25A also decreased significantly
or with strong trends at the protein level after enzalutamide
treatment in both U87MG and MGPP3 cells. Another
downstream gene GADD45A showed significant decrease in
MGPP3 cells but not in U87MG after drug treatment (Figure
2S). MGPP3 murine GBM cells showed similar AR expression
patterns and dose-dependent response to enzalutamide treatment
(Figures 3C, D). However, unlike LnCap prostate cancer cells
with nuclear specific AR distribution, both GBM cell lines cultured
in vitro showed cytosol-enriched subcellular localization of AR
which is in contrast with the nuclear dominant localization of
GBM patients’ specimens based on IHC staining.
AR Antagonists Suppress the Growth of
Spheroids and Decrease Glioma Cancer
Stem Cell Population in U87MG Cells
In Vitro
Cancer stem cells (CSCs) can be enriched in spheroids using an
ultra-low concentration of serum (43). Although the consensus
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FIGURE 1 | Histological studies of androgen receptor (AR) expression in human brain/GBM tissue. (A–C) H&E staining of a GBM slide from a male patient (40×,
100× and 400× magnification, respectively). (D–F) Positive AR expression (brown) in a GBM slide from the same patient as A (40×, 100× and 400× magnification,
respectively). (G–I) H&E staining of a GBM slide from a female patient (40×, 100× and 400× magnification, respectively). (J–L) AR staining in a GBM slide from the
same patient as G (40×, 100× and 400× magnification, respectively). Enriched AR positive cells at peri-vascular area are best shown in K (arrow). Majority of AR
staining (brown) is in nuclei in a subset of the cells (arrow in L). (M) H&E staining of a GBM specimen showing the endothelial proliferation of the vessels (arrow).
(P) AR staining of the GBM specimen from the same patient as M. (N) H&E staining of a normal human brain autopsy specimen. (Q) Negative AR staining of the
normal brain autopsy specimen from the same patient as N, at 400× magnification. (O) H&E staining and (R) scattered weakly positive nuclear staining of AR in a
temporal lobectomy surgical specimen from a patient with epilepsy, at 400× magnification.
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has not been reached on what is/are the most representative
marker(s) to detect CSCs in GBM, cell surface marker CD133 has
been the most commonly used in used (44, 45).
After the formation of spheroids of U87MG in culture media
with an ultra-low concentration of serum, incubation of the
spheroids with AR antagonists suppressed their further growth
(Figures 4A, B). In contrast, untreated (DMSO controls)
spheroids continued growing in culture media but the growth
was delayed or completely arrested with increasing
concentrations of AR antagonists added. After treatment with
either enzalutamide or bicalutamide, CD133+ cells in U87MG
spheroids were significantly decrease proportionally compared
with the control group treated with DMSO only based on flow
cytometry (Figures 4C, D). The average percentages of CSC cells
in spheroids were 3.1 ± 0.3, 2.2 ± 0.1 and 1.6 ± 0.2 in DSMO
control, enzalutamide and bicalutamide, respectively.
AR Antagonists Downregulate Cancer
Stem Cell Marker Gene Expression
in GBM Cells In Vitro in a
Time-Dependent Manner
In addition to the cell surface marker CD133, other cancer stem cell
markers/embryonic stem cell markers such as Nanog andOct4 have
also been widely used for cell linage studies in cancers including
GBM (46–50). The expression levels of Oct4 and Nanog in the
spheroids of U87MG with and without enzalutamide treatment
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FIGURE 2 | AR antagonists inhibit proliferation of human and mouse GBM cell lines in vitro. (A–D) GBM cell lines were treated with indicated concentrations of
enzalutamide for 2 days before cell titer blue assays were performed. (A) U87MG cell line (human) (IC50 = 41 mM). (B) U138MG cell line (human) (IC50 = 45 mM);
(C) Ln229 cell line (human) (IC50 = 41 mM). (D) MGPP3 cell line (mouse) (IC50 = 56 mM); (E–H) GBM cell lines were treated with indicated concentrations of
bicalutamide for 2 days before cell titer blue assays. (E) U87MG cell line (IC50 = 121 mM). (F) U138MG cell line (IC50 = 122 mM). (G) Ln229 cell line (IC50 = 72 mM).
(H) MGPP3 cell line (IC50 = 42 mM). (I) Western blotting assays demonstrate that AR and c-Myc protein levels decrease in the U87MG, MGPP3 and LnCap cells (a
prostate cancer cell line for positive control) after the treatment of enzalutamide (40 µM) time dependently. 8, 24, 48 h: cells were treated with the drug for 8, 24 or
48 h. All experiments were performed with three independent replicates.
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were studied with Western blotting experiment. We observed
enrichment in stemness markers Nanog and Oct4 in U87MG
cells over 72 h of culturing time in spheroids when treated with
solvent control only (Figure 4E). Enzalutamide treatment
significantly decreased expression of both Nanog and Oct4
proteins in spheroids after only one-day incubation with the drug
as compared to controls with DMSO treatment only. The
proportional reduction, relatively to DMSO treatment control, of
Nanog and Oct4 becamemore significant after prolonged treatment
(three days) of enzalutamide (Figure 4F). GATA4, a downstream
gene of Oct4 and Nanog, also decreased significantly in its protein





FIGURE 3 | Confocal immunofluorescence studies demonstrate that enzalutamide decreases AR (red) and c-Myc (green) in GBM cells cultured in vitro (U87MG and
MGPP3). (A) U87MG cells were treated with DMSO (negative control) or various concentrations of enzalutamide (20 µM or 40 µM). (B) MGPP3 cells were treated
with DMSO or various concentrations of enzalutamide (20 µM or 40 µM). (C) LnCap (prostate cancer cell line) served as a positive control. (D) Quantification of the
immunofluorescence signals of AR and c-Myc in U87MG and MGPP3 cell lines after enzalutamide treatment (20 µM or 40 µM) for 24 h. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
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FIGURE 4 | AR antagonists decrease the cancer stem cell population in U87MG GBM cells in vitro. U87MG spheroids were cultured in low serum medium (0.5%)
for 2 days and then treated with DMSO (negative control), enzalutamide (120 µM), or bicalutamide (180 µM) for another 4 days with diameters of spheroids
measured daily. (A) Representative figures of the U87MG spheroids before and after the treatment of enzalutamide (120 µM) or bicalutamide (60 µM). (B) Measured
diameters of the spheroids normalized to before the treatment during drug treatment with increasing concentrations of enzalutamide (40, 120, and 240 µM) or
bicalutamide (60, 180, and 360 µM). (C) Representative flow cytometry gating strategy with dissociated cells from U87MG spheroids. Upper left: no drug treatment
and no CD133 antibody staining; upper right: DMSO only (no drug treatment control); lower left: enzalutamide (120 µM); lower right: bicalutamide (180 µM). (D) CSC
populations (CD133+) were compared in dissociated cells from spheroids with or without treatment of AR antagonists using flow cytometry as shown in (C) Eight
replicates per group were used for flow cytometry with mean values presented in the histogram. (E) Western blotting assays showed decreased expression levels of
CSC markers, Nanog and Oct4, after enzalutamide treatment for 24 and 72 h. (F) Quantification of Nanog and Oct4 protein levels before and after the treatment of
enzalutamide for 24 and 72 h. All experiments were performed with three independent replicates. (G) Extreme Limiting Dilution Assays (ELDA) in vitro to estimate the
frequency of tumor sphere-forming stem-like cells in U87MG and MGPP3 cell lines. Plot of the log (e) fraction of wells without tumor spheres as a function of plated
U87MG/MGPP3 cell number/well. The more vertical the line, the higher the percentage of tumor sphere-forming cells or CSCs. (H) Extreme Limiting Dilution Assays
(ELDA) in vivo to estimate the frequency of CSCs. Plot of the log (e) fraction of mice without tumor growth as a function of implanted MGPP3 cells. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
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In Vitro and In Vivo Limiting Dilution
Assays Demonstrate That Enzalutamide
Suppresses Tumor Sphere-Forming
Capability in GBM Cells In Vitro and Tumor
Formation In Vivo
The in vitro limiting dilution assay (LDA) has been used widely to
analyze the cancer stem cell population under various culturing
conditions (51–54). Extreme limiting dilution assay (ELDA) is a
software application that calculates the proportion of cancer stem
cells in a mixed cell population with statistical software (55). Our
ELDA experiments demonstrated that enzalutamide treatment
significantly decreased the tumor sphere-forming capacities from
the subpopulation of cancer stem cells in both U87MG and
MGPP3 cell lines (Figure 4G). The inhibitory effects of the AR
antagonist are dose-dependent with 80 µM enzalutamide
exhibiting a significantly enhanced effects suppressing tumor
sphere formation/CSC subpopulation in U87MG cell line
compared with the negative control or lower concentration of
enzalutamide (40 µM). Interestingly, the inhibitory effects of
enzalutamide on tumor sphere formation in MGPP3 cells are
also significant compared to the negative control but seem to be
saturated with doses above 40 µM (Figure 4G).
LDA in vivo is the gold standard to test the tumor-initiating
capability of the CSCs. With each mouse brain inoculated with
104 MGPP3 cells, all six mice in the control group without drug
pretreatment had tumor growth as expected, whereas only three
out of six in the enzalutamide pretreated group had tumor growth
after 6 weeks. In mice inoculated with decreased number of tumor
cells at 103 cells each, one out of six mice in the control group had
tumor growth while zero out of six mice in the enzalutamide
pretreated group had tumor growth 6 weeks after implant. ELDA
software estimated that the ratios of CSCs with tumor-forming
capacity in the cell line decreased from 1/3,071 to 1/16,498 after
the treatment of enzalutamide (p = 0.022) (Figure 4H).
mRNA Expression Levels of AR Are
Positively Correlated With GBM CSC
Marker Genes as Well as Genes/Pathways
Related to Proliferation
To explore the correlation between AR gene and GBM cancer
stem cell genes in The Cancer Genome Atlas (TCGA) database, we
selected 10 well-known GBM cancer stem cell genes (45, 56). We
found that the mRNA expression levels of all GBM cancer stem
cell genes are positively correlated with the AR gene, the highest
correlation being SOX2 (Spearman’s rank correlation coefficient
R = 0.59) (Figure 5B). No correlation was seen between the
expression levels of AR and GAPDH, a housekeeping gene.
In addition, from our RNA-seq analyses on U87MG cells
cultured in vitro, we found that almost all cancer stem cell marker
genes such as Nestin, ID1, FUT4 and L1CAM showed either a
significantly decreased or trends of decreased expression (Nanog,
CD133 (Prom1), Sox2 and BMI1) after enzalutamide treatment (80
µM) for 48 h. Quantitative RT-PCR assays were further performed
and confirmed that the mRNA expression levels of AR, CD133
(Prom1), Oct4, Nanog, and Sox2 were all significantly decreased
after the treatment of enzalutamide (80 µM) for 48 h (Figure 5D).
Based on the RNA-seq results after treating U87MG cells with
enzalutamide for 48 h, comprehensive Gene Set Enrichment
Analyses (GSEA) analyses against the KEGG pathway database
(https://www.genome.jp/kegg/pathway.html [genome.jp]) were
also performed to identify additional cellular functions of AR.
Cancer stem cell signatures were included in different related
pathways. The signaling pathways regulating pluripotency of
stem cells specifically FoxO and TGF-b signaling pathways, as
expected, are listed among the top 15 pathways most affected after
enzalutamide treatment, with 32 differentially expressed genes
(DEGs) after the treatment of enzalutamide were enriched in the
“hsa04550: Signaling pathways regulating pluripotency of stem
cells” (p = 2.72 × 10−4). In addition, genes/pathways involved in
cell cycle, Hippo, MAPK, PI3K-Akt and ErbB signaling pathways
are listed as well indicating the involvement of AR in promoting
cell cycling/proliferation of differentiated GBM cells (Figure 5A).
Furthermore, the heatmap generated from RNA-seq results
confirmed the downregulation of the expression levels of not
only the genes specific for cancer stem cells but also those in TGF-
b signaling, cell cycles and cell proliferation in U87MG cells after
enzalutamide treatment time-dependently (Figure 5E).
Enzalutamide Downregulates Cancer
Stem Cell Marker Gene Expression In
Vivo, Inhibits GBM Tumor Progression and
Significantly Prolongs Survival in Mice
We further examined the effects of the AR antagonist using a
syngeneic orthotopic GBM mouse model. MGPP3 cells which
express luciferase constitutively were intracranially injected into
mice, and treatments (enzalutamide vs. vehicle control) were
administered twice per week once tumors developed.
Bioluminescence imaging was used to monitor the differences in
tumor progression between treatment groups (Figures 6A, B).
Representative IVIS images of progressed tumors (top right) and
tumors responded to enzalutamide treatment (twomice at bottom
right) are shown in Figure 7B. We found that GBM tumor growth
was suppressed (size reduced or stabilized) in five out of nine mice
(55.6%) in the enzalutamide-treated group versus zero out of nine
mice (0%) in the vehicle only control group. Mice tolerated this
dose of enzalutamide treatment well with significantly more
weight gain during the course of treatment (Figure 6C).
Furthermore, mice treated with enzalutamide had
significantly improved overall survival compared with those in
the control group (p <0.05). The median survival for the control
and enzalutamide-treated groups was 36 days and 54 days,
respectively (Figure 6D). All the mice in the control group
died by Day 72 after tumor injection whereas 50% of the mice
in the enzalutamide treated groups survived. The tumors in these
long term surviving animals completely disappeared eight weeks
after initiation of the drug treatment.
Immunohistochemistry study on formalin-fixed and paraffin-
embedded (FFPE) mouse brain tumor tissue demonstrated that
cell surface CSCmarker CD133 and oncogene c-Myc expressions
were both significantly decreased in enzalutamide-treated mice
tumors compared with those in control group (Figures 6E, F).
It was also interesting to observe that although the percentages
of AR-positive cells in the tumor did not show significant
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differences between enzalutamide-treated and control
groups, the AR expression levels or IHC staining intensity was
decreased after enzalutamide treatment. Comparing with the
control tissues without drug treatment showing AR staining
mostly in the nuclei (95.4%), the tumor brain specimen after
enzalutamide treatment showed a significantly higher percentage
of cells with cytosol dominant distribution (96.7%) (p <0.05)
(Figure 6E).
All CD133+ Cells Are AR Positive In Vivo
But AR Expression Is Not Specific for
Glioma CSCs
Confocal microscopy was performed to study the expression
patterns of AR and glioma CSC marker genes on FFPE mouse
brain tumor specimens. AR in orthotopically growing tumor
cells showed variable staining intensities (Figure 7A) and





FIGURE 5 | AR positively correlates with CSC marker genes at mRNA expression level. (A) Gene Set Enrichment Analyses (GSEA) against the KEGG pathway
database showing the top 15 pathways most significantly regulated in the U87MG cells with differentially expressed genes (DEGs) after the treatment of enzalutamide
for 48 h. (B) The positive correlations of mRNA expressions between CSC marker genes and AR from in vivo RNA-seq results in GBM patients from TCGA
database. GAPDH, a housekeeping gene, showed no correlation with AR (R = -0.03). (C) mRNA expression levels of various CSC marker genes in U87MG cells
cultured in vitro before and after the treatment of enzalutamide (80 µM) from RNA-seq results from our laboratory. CD133 is an alias name for Prom1.
(D) Quantitative RT-PCR results of the representative CSC genes after the treatment of enzalutamide. (E) Heatmap of the genes specific for cancer stem cell, TGF-b
signaling pathway, cell cycle, and cell proliferation responding to enzalutamide treatment in U87MG cells at different time points. The scale bar at the bottom
represents the normalized read counts of the genes from RNA-seq results. *p < 0.05.
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in cytosol (Figure 7B). Clusters (thick arrow) as well as
individually distributed (arrowheads) CD133+ CSCs were
shown in Figure 7A. CD133 staining pattern was consistent
with a cell membrane distribution (Figure 7B). Due to the
different subcellular distribution patterns, co-localization rates
of AR and CD133+ cell were manually counted. All CD133+ cells
(100.0% ± 0.0%) were positively stained for AR. It is interesting





FIGURE 6 | Enzalutamide suppresses CSC marker gene expression, GBM tumor growth in vivo and prolongs overall survival in treated mice with MGPP3 cells
implanted in brain. (A) Fold changes of the bioluminescent signals of the tumors in brain after the treatment of vehicle only or enzalutamide (20 mg/kg, three times
per week, IP). (B) Representative IVIS images of the tumor growth in mouse brain after vehicle only or enzalutamide treatment. Wk 0, 3 and 5: IVIS imaging taken
prior to (week 0), 3 and 5 weeks after initiating of drug injection. Mann–Whitney U tests were performed in both (A, B) to compare between groups. (C) Weight
changes of the mice after the treatment. (D) Overall survival was significantly improved in mice treated with enzalutamide comparing with vehicle only.
(E) Representative images of the mouse brain tissue after IHC staining for CD133 (100×), c-Myc (200×), and AR (200×). Corner image (left upper corner of the left
panel): high magnification image showing tumor cells with positive AR staining with nuclear localization without enzalutamide treatment. Corner image (left upper
corner of the right panel): high magnification image showing tumor cells with positive AR staining but more cytosol distribution after enzalutamide treatment.
(F) Quantifications of positive cells in the brain tumors from IHC staining after vehicle only or enzalutamide treatment. Two-tailed student t tests were performed for
statistical comparisons. *p < 0.05; **p < 0.01.
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high rate of co-localization with cells with higher intensity of AR
staining defined by >50% or maximal intensity (91.3% ± 7.5%)
(arrowheads, Figure 7A). Clusters of CD133+ CSCs, as in the
dash line box in Figure 7A, were all AR positive but not always in
high AR intensity cells (Figure 7B). AR expression in CD133-
negative (AR+/CD133−) cells was also seen but mostly (80.2% ±
8.3%) in cells with lower intensity of AR staining (thin arrows,
Figures 7A, B). The staining pattern indicates that higher AR
expression level is associated with cells with higher stemness.
Similarly, All Nanog-expressing (Nanog+) cells were AR+ per
manual counting. More impressively, the Nanog-weighted
Nanog/AR co-localization coefficient equaled 0.75 based on
software analyses which means 75% of positive Nanog staining
signals co-localize with AR staining. Again we noticed that
Nanog+ cells tend to have stronger AR stainings as well with
nearly all Nanog+ cells (89.5% ± 10.1%) showing AR signal
intensities above the 50% threshold of the maximum
(arrowheads, Figure 7C). In contrast, a large portion of AR+
cells (76.7% ± 10.2%) showed no detectable Nanog staining (thin






FIGURE 7 | Immunofluorescence confocal microscopy on mouse GBM FFPE specimen (5 µm thickness) showing the subcellular localizations of AR (green), CD133
(pink) and DAPI-stained nuclei (blue). (A) Low magnification images (10×) and (B) high magnification images (63×) which were scanned from areas in the dash line
boxes in (A) demonstrated co-expression of CD133 in AR-expressing (AR+) cells with high staining intensity (arrowheads). AR expression can be seen in CD133
negative cells but with low AR staining intensity (thin arrows). (C) High magnification images (63×) demonstrated co-expression of Nanog in AR+ cells with high AR
staining intensity (arrowheads). Cells with negative Nanog staining could be AR+ but showed weaker AR staining intensities than Nanog+ cells (thin arrows). (D) High
magnification images (63×) with slides stained with secondary antibodies only as negative controls. (E) Schematic figure showing the proposed mechanisms of AR
antagonists inhibiting both cancer stem cells maintenance and cancer proliferation from more differentiated cells. CSC, cancer stem cell; PDCC, partially differentiated
cancer cell; DCC, differentiated cancer cell.
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showed weak AR staining intensity (≤50% of maximum)
(90.2% ± 5.1%), but still significantly higher than the
background as shown in the negative control (Figure 7D).
Data further supporting these observations were from the
software-based co-localization analyses which showed that AR-
weighted Nanog/AR co-localization coefficient was 0.09, in
contrast to 0.75 for Nanog-weighted number. The results were
interpreted as: although all Nanog+ cells were also AR+ and
Nanog protein staining heavily co-localized with AR protein, AR
expression was much more diffusely seen in tumor cells than
Nanog due to the findings that many weakly AR+ cells were
Nanog negative.
DISCUSSION
The presence of specific steroid hormone (estrogen, progesterone,
or androgen)-binding receptors has been correlated with the
clinical outcome and response to hormonal therapy in a
number of different neoplasias, including breast, prostate and
renal cell carcinoma (57). However, there is much less information
available in brain tumors for steroid hormone receptor
expressions or response to hormonal—particularly androgen—
suppression. Previous studies, as well as our own, showed that
androgen receptors were consistently detected in a higher
proportion of gliomas (17, 27, 28, 31). These findings may help
to explain the gender difference in GBM incidence and indicate
that ARmight be a promising therapeutic target for treating GBM.
Surprisingly, we have found a similar high proportion of GBM
in female patients that expresses AR, and a GBM cell line derived
from a female patient, Ln229, also responds to androgen receptor
antagonists in a way similar to cell lines derived frommale patients
(Figure 2). The role of AR in gliomagenesis in female patients is
worth further studying. It has been reported that following brain
injury in rodent and bird models, astrocyte aromatase expression
is upregulated transiently starting from hours post-injury and
lasting for a few weeks (58–60). These data provide a possible
mechanism for the upregulation of AR and/or secondary AR self-
activation through aromatase-mediated testosterone conversion/
depletion, which chronically could induce AR overexpression and/
or become androgen independent. Ovary and adrenal glands
produce dehydroepiandrosterone (DHEA), androstenedione and
testosterone. Furthermore, for postmenopausal women, the
common age for GBM diagnosis, the ovary becomes an
androgen-secreting organ (61). Androgen antagonists thus may
play an equally therapeutic role in both genders.
We have observed for the first time very consistent results
from our studies both in vitro and in vivo that AR blockade
downregulates the expression levels of majority of the tested GBM
CSC-specific marker genes. Cell culture studies showed significant
reductions of cancer stem cell genes at both mRNA and protein
levels in both human and mouse cell lines cultured anchorage
dependently as well as in tumor spheroids. AR genes are very
conservative between human and mouse. AR antagonists
significantly suppress the expression of c-Myc, whose activity is
required for proliferation, growth, and survival of glioma CSCs
(56). The results strongly suggest that AR may be involved in the
process of gliomagenesis and act as an essential factor for glioma
CSC maintenance and/or proliferation, which is consistent with
the findings that androgen/AR promotes neural stem cell
proliferation (62). We acknowledge that the functions of
androgen/AR in embryonic and somatic stem cells have been
shown to be tissue type-dependent, and the role of AR in cancer
stem cells have been controversial which again demonstrates the
significance of our studies (63, 64). Supporting evidence for our
hypothesis further stems from observations that AR expression is
induced in the glial cells in animal brains after injuries (excitotoxic
injury or stab wound induced) in both male and female rat and
avian models (65, 66). Although there is some discrepancy on
whether reactive astrocytes or microglial cells are the source of an
overexpression of AR, the data do suggest that AR might be
playing a role in pathological conditions such as carcinogenesis in
glial cells. In the rat model, AR was seen to be expressed at low
levels in some cortex and hippocampal neurons but not in non-
stimulated astrocytes, and no overexpression was seen in neurons
adjacent to injury site. In mouse GBM specimens, we found
negative staining of AR in adjacent and contralateral normal brain
tissue. It is interesting to note that in patients with epilepsy, their
temporal lobectomy tissue also showed some degree of elevation
of AR expression when compared to brain tissues from autopsy of
normal brain which again suggests the possible involvement of
AR in the pathologic process of brain (Figure 1).
It is still debatable which CSC marker genes currently studied
represent true stemness in these precursor tumor cells. Thus we
have combined both in vitro and in vivo studies including tumor
spheroid formation assays, limiting dilution assays in vitro and in
vivo, CSC marker studies from TCGA database and from our
RNAseq studies as well as IHC and confocal microscopy on
multiple CSC marker genes to confirm that AR is essential for
maintenance of glioma CSC population. Our results are consistent
with other studies demonstrating that AR can bind directly to
Nanog gene promotor and promote cancer cell stemness in
hepatocellular carcinoma and ovarian cancer (67, 68). Although
our in vivo tumor model demonstrated a high percentage of CSCs
in mouse GBM by IHC and confocal microscopy, there are very
low abundance of CD133+ cells when GBM cells were cultured in
vitro. Our findings are consistent with what have been reported
previously that in vitro cultured GBM cells contain a very low
percentage (0.3–5%) of CD133+ cells particularly in high serum
conditions which induce differentiated state of the tumor cells that
are CD133− (69–72). Meanwhile, Jensen et al. reported that, when
they implanted the U87MG cells into the mouse brain, they found
that there was 30–40% CD133+ cells in the mouse GBM tissue
developed, significantly higher than that in in vitro conditions.
Interestingly, CD133+ cells also exhibited clustered distribution
pattern in the culture tumor spheroids and brain tumor tissue as
seen in our studies (Figure 6E) (73). However, AR antagonists,
both enzalutamide and bicalutamide, demonstrated significant
efficacy in suppressing cell proliferation after only two days of
treatment in cultured GBM cell lines indicating that AR may not
only promote CSCs but also cell proliferation. Indeed, our
unpublished studies also showed that blocking AR could induce
Zhao et al. AR Antagonists Suppress Glioma Stem Cells
Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 61662514
G2/M cell cycling arrest in GBM cell lines. AR blockade can
significantly downregulate c-Myc protein levels in GBM cells both
in vitro and in vivo (Figures 2 and 6) with known cellular
functions of c-Myc in cell proliferation and glycolysis in
glioblastomas (74, 75). Gene ontology from RNA-seq results
also confirmed the additional functions of AR in cell cycling/
proliferation particularly by regulating Hippo, PI3K/Akt and
MAPK signaling pathways which can all contribute to both CSC
and differentiated cancer cell divisions (Figure 5). Our results
from confocal microscopy also confirmed that AR expression can
be detected in both CD133+ and CD133− tumor cells although AR
expression levels, as indicated by staining intensity, were shown to
be highest in isolated CD133+ cells than clustered CD133+ cells
and AR+/CD133− cell (Figures 7A, B). Similar results were found
using Nanog as another CSC marker (Figure 7C). Questions still
remain whether the higher AR staining intensity is due to higher
protein expression level or protein aggregation in cells. Based on
these results, we hypothesize that glioma CSCs may be more
dependent on AR expression/functions for maintenance and/or
survival than more differentiated tumor cells. Cancer stem cells
(CSCs), although composing only a small portion of the tumor cell
population, have the highest AR expression levels/staining
intensities (AR+++) which decrease as the CSCs differentiate
into partially differentiated cancer stem cells (PDCCs) (AR++)
and subsequently into differentiated cancer cells (DCCs) with the
lowest AR expression level/intensity (AR+) (Figure 7E).
We are currently conducting further experiments including
overexpression of c-Myc in GBM cell lines to potentially
overcome the effects from AR suppression, as well as CRISPR/
CAS9-mediated AR knockout in GBM cell lines to investigate the
multi-faceted functions of AR in GBM tumor growth.
Nonetheless, the particular efficacy of AR blockade in
suppressing glioma CSCs signify the importance of further
research on this novel target with its potential to overcome the
tumor resistance mediated by CSCs to current standard care with
RT and/or chemotherapy.
AR antagonists have been used to treat prostate cancer for
more than 35 years with extensive clinical experience and
accumulation of biological data (76). Enzalutamide, a new
generation of AR blockade drug that is FDA-approved for
metastatic prostate cancer, which also demonstrated excellent
brain penetration capability, provides us a readily testable drug
for repurposing in GBM patients (77). Enzalutamide, unlike the
previous generations of AR antagonist drugs such as bicalutamide
and flutamide, not only can prevent androgen and AR binding,
but also block the nuclear import of AR including some of the AR
splicing variants (AR-Vs). AR-Vs have been reported to contribute
to prostate cancer progression through induction of epithelial-to-
mesenchymal transition and acquisition of stem cell
characteristics (78). The expression of AR-Vs lacking the c-
terminal ligand-binding domain (LBD) was found to be
increased in androgen-independent and metastatic prostate
cancers (79, 80). Some of these AR-Vs such as AR-V7, are
constitutively active and localized in the nuclear compartment,
and their transcriptional activity is not regulated by androgens.
However, Zhan et al. (81) also reported that, when expressed alone
in cells, some AR-Vs (e.g., AR-V1, AR-V4, and AR-V6) localize
mainly in the cytoplasm but can dimerize with AR-V7 or widetype
AR to be nuclear localized. There is very limited information on
whether AR-Vs are present in GBM except for a preliminary study
from Zalcman et al., indicating ~30% of the glioblastomas in
patients expressed a constitutively active AR-splice-variant (AR-
V7/AR3) lacking the LBD (30). Whether AR-V7 is expressed in
U87MG cells are controversial (30, 82, 83). No information exists
whether other types of AR-Vs present in GBM although data from
Zalcman et al. strongly indicate the presence of castration-
resistance of the tumor from the very beginning of pathogenesis
of GBM which is different from prostate cancer that usually
becomes so after prolonged androgen deprivation therapy. If
that is the case, enzalutamide and other newly generation of AR
antagonists such as apalutamide could provide superior GBM
control benefit compared to older generation drugs or antagonists/
agonists of gonadotropin-releasing hormone (GnRH) that
suppress androgen production, as having been demonstrated by
a phase III clinical trial on metastatic prostate cancer (84). Our
results showed that, when cultured in vitro, GBM cells including
the mouseMGPP3 cells had cytosol dominant distribution pattern
of AR (Figure 2) with or without enzalutamide treatment.
However, IHC staining on both mouse and human brain tumor
specimens demonstrated nearly 100% nuclear localization of AR
but more cytosol dominant distribution pattern after enzalutamide
treatment in vivo. These results, although cannot conclude
whether there are cytosol-located AR-Vs in these GBM cells, do
indicate that the testosterone concentrations in culture medium
might not be high enough as in brain tissues to induce
translocation of AR to nucleus when cultured in vitro. Our
results also provided evidence that enzalutamide can successfully
block the AR translocation to the nucleus as reported before (85).
With our results in GBM and previous studies from prostate
cancer showing specific cancer stem cell suppression, AR
antagonists could be good therapeutic candidates and
repurposed in the treatment of GBM, particularly when
combined with current standard care modalities such as
temozolomide and/or radiation therapy, which cancer stem
cells are known to be resistant to (3, 86, 87). We also
acknowledge that in vitro effective dose of enzalutamide in
GBM cells (IC50: ~40 µM) or for spheroids (60–120 µM) from
our study seems to be higher than the therapeutic dose in plasma
achievable in vivo. The phase I/II study revealed that the
minimum (predose) plasma concentrations (Cmin) at steady
state in the 150 mg PO daily dose cohort of patients for
enzalutamide is about 20 µM although nearly doubling of the
concentration can be achieved if using maximal toxicity dose (88).
Preclinical studies on prostate cancer cells demonstrated Ki
(inhibition constant) of enzalutamide is 86 nM and the IC50 of
enzalutamide to suppress widetype AR activation by testosterone
based on reporter gene transcription assays is 219 nM. The IC50
of enzalutamide in cell viability assays for VcaP, an AR dependent
prostate cancer cell line, is 410 nM (89). These numbers are
drastically lower than the IC50s of cell proliferation assays we
observed in GBM cell lines. One explanation of the difference is
the difference in experimental conditions. For example, the
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culturing time after adding the drug prior to cell proliferation
assays was much longer than ours (4 days vs. 2 days). The reason
we chose 2 days culturing time after adding the drug instead of 4
days is that after 3 days, we started to see synchronized cell
apoptosis in U87MG and other GBM cell lines such as U138MG
which develops rapidly (data not shown). It is noted that in the
studies by Zalcman et al., the concentrations of enzalutamide used
to treat GBM cells for 48 h, same as what we did, were from 10 to
80 µM, consistent to our data (30). We also would like to point
out that the IC50s reported by Moilanen et al. was measured
under testosterone stimulation (mibolerone) which very likely
would have caused left-shift of the survival curve. However, Xue
et al. reported that the IC50s of enzalutamide on different prostate
cell lines such as LnCap, C4-2B, 22Rv1 and VCaP were 42, 20, 36,
and 30 µM without testosterone stimulation (90). Although the
authors did not specify the culturing time for each cell line after
adding the drug but stated the shortest culturing time is 72 h.
These IC50s are very similar to our results from GBM cell lines
and probably reflecting the conditions in vivo better with the
testosterone levels in elderly patients, male or female, being very
low around the average ages of GBM diagnosis. Another
explanation on higher IC50s seen in GBM cell lines is the
potential presence of AR-Vs, as discussed above that may
render GBM cells much more resistant to AR antagonists
comparing to androgen-dependent prostate cancer cells, which
will keep us in mind when developing future clinical trials
repurposing AR antagonists for GBM treatment. Despite of
these explanations, enzalutamide in this range of concentrations
(40–80 µM) might involve a non-canonical target(s) with off-
target effects which warrants further studies. Arguing against this
hypothesis are the published data showing that knocking down of
AR by siRNA resulted in significant inhibitory effects on GBM
cell growth in vitro although whether the effects were mainly on
differentiated tumor cells or CSCs is unclear (30).
Nevertheless, our results support the potential of repurposing
AR antagonists for GBM treatment. Enzalutamide showed
significant efficacy in the syngeneic orthotopic mouse GBM
model, although well tolerated, only 50% of the mice survived
long term (Figure 6).We did observe significantly more weight gain
in drug-treated mice which is a well-known side effect of androgen
deprivation therapy. It is also noted that the survival curve after
enzalutamide treatment showed initially the same pattern as control
group but separated eventually indicating a heterogeneity of tumor
response to the drug. Our pre-clinical results indicate that likely
further dose escalation study for GBM patients or combining this
drug with other standard care modalities for GBM such as
temozolomide and/or RT may be necessary to further improve
the outcome, as supported by themost recently published data from
Werner et al. in the flank implant tumor model (31).
In summary, our data demonstrated tumor suppressive effects of
AR antagonists, particularly enzalutamide, in GBM cell lines and, for
the first time, in an orthotopic mouse model. Potential mechanism of
the drug effects appear to be at least partly mediated through
inhibition of cancer stem cell via AR in gliomagenesis and may
provide us with a novel target for GBM treatment.
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